Skip to main content
Retour
Watch Compare

GALECTIN THERAPEUTICS INC

Qualité des données : 83%
GALT
Nasdaq Manufacturing Chemicals
2,41 €
▲ 0,19 € (8,56%)
Cap. Boursière: 158,64 M
Prix
2,41 €
Cap. Boursière
158,64 M
Fourchette du Jour
2,21 € — 2,41 €
Fourchette 52 Semaines
1,21 € — 7,13 €
Volume
273 728
Ouverture 2,21 €
Moyenne 50J / 200J
2,94 €
18,07% below
Moyenne 50J / 200J
3,96 €
39,07% below

Quick Summary

Points Clés

Negative free cash flow of -23,88 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,09
Interest Coverage-2,74

Valorisation

PE (TTM)
-5,14
En dessous de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -5,1 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

MEDX logo MEDX Horizon Kinetics Medical ETF
1,27% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -30,84 M
ROE N/A ROA -216,64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -23,88 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,09
Interest Coverage -2,74 Asset Turnover N/A
Working Capital -123,72 M Tangible Book Value -125,30 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,14 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -15,05%
Market Cap 158,64 M Enterprise Value 147,12 M
Per Share
EPS (Diluted TTM) -0,48 Revenue / Share N/A
FCF / Share -0,36 OCF / Share -0,36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 77,43%
SBC-Adj. FCF -25,85 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -30,84 M -47,05 M -41,07 M -38,78 M -30,53 M
EPS (Diluted) -0,48 -0,76 -0,74 -0,65 -0,52
Gross Profit — — — — —
Operating Income -20,09 M -42,43 M -38,07 M -38,35 M -30,18 M
EBITDA — — — — —
R&D Expenses 14,29 M 36,57 M 32,13 M 31,74 M 23,82 M
SG&A Expenses — — — — —
D&A — 0,0 0,0 0,0 0,0
Interest Expense 7,33 M 5,54 M 2,79 M 1,03 M 489 000,0
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 19,53 M 17,50 M 28,20 M 21,29 M 41,83 M
Total Liabilities 145,73 M 120,57 M 88,44 M 53,48 M 39,21 M
Shareholders' Equity -127,92 M -104,79 M -61,96 M -33,92 M 893 000,0
Total Debt — — — — —
Cash & Equivalents 17,72 M 15,12 M 25,66 M 18,59 M 39,65 M
Current Assets 19,44 M 17,25 M 27,71 M 20,55 M 41,82 M
Current Liabilities 8,03 M 35,41 M 15,68 M 13,01 M 9,03 M